Targeting activated KIT signaling for melanoma therapy

Journal of Clinical Oncology

Volumn 31, Issue 26, 2013, Pages 3288-3290

  Bastian, Boris C ^a   Esteve Puig, Rosaura ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; KIT PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STEM CELL FACTOR RECEPTOR;

ALLELE; ARTICLE; CANCER THERAPY; ENZYME ACTIVATION; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE DOSAGE; GENE TARGETING; HUMAN; LOSS OF FUNCTION MUTATION; MELANOCYTE; MELANOMA; MESENCHYME; MOLECULARLY TARGETED THERAPY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PROGNOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION;

EID: 84891529909     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3227     Document Type: Article

References (24)

1. Whiteman DC, Pavan WJ, Bastian BC: The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 24:879-897, 2011
2. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006
3. Park E, Yang S, Emley A, et al: Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi. Am J Dermatopathol 34:41-46, 2012
4. Bastian BC, Kashani-Sabet M, Hamm H, et al: Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60:1968-1973, 2000
5. North JP, Kageshita T, Pinkel D, et al: Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma. J Invest Dermatol 128:2024-2030, 2008
6. Liang R, Wallace AR, Schadendorf D, et al: The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma. Pigment Cell Melanoma Res 24:714-723, 2011
7. Monsel G, Ortonne N, Bagot M, et al: C-Kit mutants require hypoxia-inducible factor 1 to transform melanocytes. Oncogene 29:227-236, 2009
8. Kong Y, Si L, Zhu Y, et al: Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17:1684-1691, 2011
9. Minor DR, Kashani-Sabet M, Garrido M, et al: Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18:1457-1463, 2012
10. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334, 2011
11. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31:3182-3190, 2013
12. Lutzky J, Bauer J, Bastian BC: Dosedependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492-493, 2008
13. Hodi FS, Friedlander P, Corless CL, et al: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046-2051, 2008
14. Brown MC, Casasola RJ: Complete response in a melanoma patient treated with imatinib. J Laryngol Otol 126:638-640, 2012
15. Woodman SE, Trent JC, Stemke-Hale K, et al: Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Mol Cancer Ther 8:2079-2085, 2009
16. Eton O, Billings L, Kim K, et al: Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). J Clin Oncol 22:717s, 2004 (suppl; abstr 7528)
17. Ugurel S, Hildenbrand R, Zimpfer A, et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405, 2005
18. Wyman K, Atkins MB, Prieto V, et al: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 106:2005-2011, 2006
19. Kluger HM, Dudek AZ, McCann C, et al: A phase 2 trial of dasatinib in advanced melanoma. Cancer 117:2202-2208, 2011
20. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
21. Krauthammer M, Kong Y, Ha BH, et al: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-1014, 2012
22. Hodis E, Watson IR, Kryukov GV, et al: A landscape of driver mutations in melanoma. Cell 150:251-263, 2012
23. Heinrich MC, Maki RG, Corless CL, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359, 2008
24. Packer LM, Rana S, Hayward R, et al: Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drugresistant chronic myeloid leukemia. Cancer Cell 20: 715-727, 2011